News on cancer research & diagnostics, liquid biopsy, and cancer risk testing.
At the Business in Personalized Medicine Summit last week, the company also said it has generated promising data from a pilot study for early detection of lung cancer.
Each share comes with an accompanying warrant to purchase one share of common stock. Biocept expects to use proceeds to fund ongoing operations.
The partners will evaluate patients' responses to immunotherapeutic drugs, including PD-1 and PDL-1 inhibitors, based on bladder cancer subtypes.